

Breast Cancer HER2-Positive Breast Cancer

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Trial Status
Completed

Trial Runs In
5 Countries

Trial Identifier
NCT02913456 MO39146

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrollment.

Hoffmann-La Roche

Sponsor

Phase

NCT02913456 MO39146

Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years

Healthy Volunteers
No
